Balanced Opioid-free Anesthesia with Dexmedetomidine versus Balanced Anesthesia with Remifentanil for Major or Intermediate Noncardiac Surgery

• Published in: Anesthesiology (Philadelphia) Vol. 134; no. 4; pp. 541 - 551
• Main Authors: Beloeil, Helene, Garot, Matthias, Lebuffe, Gilles, Gerbaud, Alexandre, Bila, Julien, Cuvillon, Philippe, Dubout, Elisabeth, Oger, Sebastien, Nadaud, Julien, Becret, Antoine, Coullier, Nicolas, Lecoeur, Sylvain, Fayon, Julie, Godet, Thomas, Mazerolles, Michel, Atallah, Fouad, Sigaut, Stephanie, Choinier, Pierre-Marie, Asehnoune, Karim, Roquilly, Antoine, Chanques, Gerald, Esvan, Maxime, Futier, Emmanuel, Laviolle, Bruno
• Format: Journal Article
• Language: English
• Published: United States Lippincott, Williams & Wilkins 01-04-2021
• Subjects: Analgesics, Non-Narcotic - therapeutic use; Analgesics, Opioid - therapeutic use; Balanced Anesthesia - methods; Dexmedetomidine - therapeutic use; Female; Humans; Life Sciences; Male; Middle Aged; Pain, Postoperative - drug therapy; Pharmaceutical sciences; Prospective Studies; Remifentanil - therapeutic use; Single-Blind Method; Treatment Outcome
• ISSN: 0003-3022; 1528-1175
• DOI: 10.1097/ALN.0000000000003725

It is speculated that opioid-free anesthesia may provide adequate pain control while reducing postoperative opioid consumption. However, there is currently no evidence to support the speculation. The authors hypothesized that opioid-free balanced anesthetic with dexmedetomidine reduces postoperative opioid-related adverse events compared with balanced anesthetic with remifentanil.
Patients were randomized to receive a standard balanced anesthetic with either intraoperative remifentanil plus morphine (remifentanil group) or dexmedetomidine (opioid-free group). All patients received intraoperative propofol, desflurane, dexamethasone, lidocaine infusion, ketamine infusion, neuromuscular blockade, and postoperative lidocaine infusion, paracetamol, nefopam, and patient-controlled morphine. The primary outcome was a composite of postoperative opioid-related adverse events (hypoxemia, ileus, or cognitive dysfunction) within the first 48 h after extubation. The main secondary outcomes were episodes of postoperative pain, opioid consumption, and postoperative nausea and vomiting.
The study was stopped prematurely because of five cases of severe bradycardia in the dexmedetomidine group. The primary composite outcome occurred in 122 of 156 (78%) dexmedetomidine group patients compared with 105 of 156 (67%) in the remifentanil group (relative risk, 1.16; 95% CI, 1.01 to 1.33; P = 0.031). Hypoxemia occurred 110 of 152 (72%) of dexmedetomidine group and 94 of 155 (61%) of remifentanil group patients (relative risk, 1.19; 95% CI, 1.02 to 1.40; P = 0.030). There were no differences in ileus or cognitive dysfunction. Cumulative 0 to 48 h postoperative morphine consumption (11 mg [5 to 21] versus 6 mg [0 to 17]) and postoperative nausea and vomiting (58 of 157 [37%] versus 37 of 157 [24%]; relative risk, 0.64; 95% CI, 0.45 to 0.90) were both less in the dexmedetomidine group, whereas measures of analgesia were similar in both groups. Dexmedetomidine patients had more delayed extubation and prolonged postanesthesia care unit stay.
This trial refuted the hypothesis that balanced opioid-free anesthesia with dexmedetomidine, compared with remifentanil, would result in fewer postoperative opioid-related adverse events. Conversely, it did result in a greater incidence of serious adverse events, especially hypoxemia and bradycardia.